Cybin Inc announces acquiring a Phase 1 DMT study from Entheon Biomedical, at a purchase price of CAD$1 million plus additional considerations.
INVESTOR PROFILE | Ionic Brands
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
52-Week
Range N/A
Range N/A
Current
Outstanding 108,436,715
Outstanding 108,436,715
Warrants
Options
Fully Diluted
Market Cap.
14,639,000
14,639,000
IONIC BRANDS (CSE: IONC) has a premium portfolio of cannabis concentrate consumer brands. Ionic Brands is one of the top selling concentrate company in Washington State.
Company Brief
Ionic Brands (CSE: IONC) is creating a multi-state, consumer focused, premium cannabis porfolio consisting of iconic national brands.
They have:
- Stylish products
- World Class Management Team
- A proven and repeatable strategy for success
Highlights
Experienced and proven luxury cannabis concentrates brand
One of the tops selling vape brands in WA State with a loyal customer base
Largest standalone oil manufacturer in the state of WA
Consistent sales growth over 3 years with a verified marketing blueprint
Offers investors exposure to a premium luxury cannabis brand
Demonstrated to have a winning formula to become the top vape company in WA
Massive growth opportunity available with expansion into OR, NV and CA
In The News
Ionic Is Changing the Face of Cannabis and Creating a Social Revolution
It’s all in the URL: Ionic.social. “We believe our products are best when enjoyed in a social setting,” said co-founder Christian Struzan.
READ MORE
Marijuana Vaping Is The Most Explosive Growth Play In Marijuana Today
“Nobody smokes marijuana anymore, they vape it.” - New York Times That's not quite true. But it will be soon.
READ MORE
How To Invest In Marijuana Vaping
The marijuana vaporization products (or just "vape") market is set to explode in 2019.
READ MORE
Related Articles
Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy
Cybin announces publication of EMBARK, a model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing.
Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder
Cybin Inc announces the submission of an Investigational New Drug application (IND) to the FDA for a Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).
Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health
Optimi Health announces a new supply agreement with Filament Health to supply Filament with psilocybin mushrooms.
Novamind Reports Fiscal Q3 2022 Financial Results and Operating Highlights
Novamind Inc reports its Q3 for fiscal 2022. Quarterly revenues of CAD$3,227,352 represent a q-o-q of 32%. Novamind also expanded into the Arizona market in Q2 with its clinic operations.
Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.
Optimi Health announces entering into a supply agreement with Halucenex Life Sciences Inc that "pertains to the entirety of" Optimi's recently cultivated psilocybe mushrooms.